$250 millionHealthcare
Multiples-backed BDR Pharma buys control of Acme's oral solids unit
Oral solid formulations business of Acme Formulation, bought from existing investors including PAG, with an expected value of about $250 million.
BDR Pharmaceuticals International
1 add-on
1 deal covered
Backed by Multiples Private Equity. In our coverage since November 8, 2026.